All regulations
Nonrulemaking
FDA
Open for Comments
FDA-2025-E-3074
Patent Term Extension Application for EMRELIS (telisotuzumab vedotin-tllv), Patent No. 10,603,389
Documents
6
Comments
0
Key Dates
Comment Period OpensAug 14, 2025
Comment Period ClosesJun 3, 2026
Documents
| Type | Title | Status |
|---|---|---|
Notice |
Keywords
CDER
AbbVie Manufacturing Management Unlimited
Company
Covington and Burling LLP
Patent Term Extension Application for
EMRELIS telisotuzumab vedotin-tllv
Patent No 10603389
OPEN
Data from Regulations.gov